Biocurepharm Korea, a subsidiary of Biocure Technology Corp., of Vancouver, British Columbia, closed a convertible debt financing. The company grossed CA$445,600 (US$335,000) issuing 4 units at CA$111,400 per unit.

Centrexion Therapeutics Corp., of Boston, updated its S-1 filing with the SEC with financial results for the six months ended June 30, 2019. The company had previously filed to go public in October 2018, but postponed the proposed $86 million IPO.

Inventiva SA, of Daix, France, raised €8.2 million (US$9.06 million) selling shares at the closing price of Sept. 18, without any discount to New Enterprise Associate, BVF Partners LP and Novo Holdings A/S. Sofinnova Partners has expressed interest in buying 313,936 shares on similar terms, which may occur by the end of October. Shares of Inventiva (EPA:IVA) closed up €0.20, or 10%, to €2.19 on Thursday.

Provention Bio Inc., of Oldwick, N.J., priced its previously announced public offering of 5 million shares at $8 per share, grossing the company $40 million. The underwriters have a 30-day option to purchase an additional 750,000 shares. SVB Leerink and Cantor Fitzgerald & Co. are acting as joint bookrunning managers for the offering, while H.C. Wainwright & Co. is acting as lead manager. The deal is scheduled to close on or about Sept. 23. In a separate private placement, Provention Bio sold 2.5 million shares at $8 per share to Amgen Inc., of Thousand Oaks, Calif., grossing the company $20 million. Provention plans to use the proceeds from both offerings for general corporate purposes, including funding the advancement of its pipeline. Shares of Provention (NASDAQ:PRVB) closed down $1.37, or 14%, to $8.29 on Thursday.

VBI Vaccines Inc., of Cambridge, Mass., priced its previously announced public offering of 70 million shares at 50 cents per share, grossing the company $35 million. The underwriters have a 30-day option to purchase an additional 10.5 million shares. Raymond James & Associates Inc. and Oppenheimer & Co. Inc. are acting as joint book-running managers, and National Securities Corp. is acting as lead manager. VBI plans to use the proceeds to progress its pipeline, including funding the phase III Constant study for Sci-B-Vac, a trivalent hepatitis B vaccine, as well as regulatory submissions and pre-commercialization activities for the drug. The deal is expected to close on or about Sept. 23. Shares of VBI (NASDAQ:VBIV) closed down 18 cents, or 27%, to 49 cents on Thursday.

No Comments